NASDAQ$TYRA
Tyra Biosciences Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Tyra Biosciences reported financial results for the fourth quarter and full year 2021, highlighting pipeline progress and a strengthened organization.
Tyra Biosciences reported a net loss of $9.9 million for the fourth quarter of 2021, compared to a net loss of $3.7 million for 2020. The company's research and development expenses were $7.2 million for the quarter, and they ended the year with $302.2 million in cash and cash equivalents.
- Advanced TYRA-300 (FGFR3 inhibitor) and TYRA-200 (FGFR2 inhibitor) with IND submissions on track for mid-2022 and second half of 2022, respectively.
- Strengthened the clinical team with the appointment of Allison Kemner as Vice President, Clinical Sciences and Operations.
- Tyra Biosciences was added to the Russell 2000 Index on December 20, 2021.
- Ended the year with $302.2 million in cash and cash equivalents.
Headline financials
Revenue & EPS history
Tyra Biosciences · Revenue · Quarterly
$0
Forward guidance
Tyra Biosciences is focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. They expect to submit Investigational New Drug Applications (INDs) to the U.S. Food and Drug Administration (FDA) this year for TYRA-300 and TYRA-200.
Tailwinds
- Potential to develop next-generation targeted therapies that improve clinical outcomes.
- Expected IND timing for TYRA-300 and TYRA-200.
- Progress and planned advancement of our development pipeline.
- Expanding the nomination of clinical candidates from our FGFR3-related skeletal dysplasia, RET and FGFR4 programs.
Headwinds
- Early in development efforts, have not tested any of our product candidates in clinical trials.
- The approach we are taking to discover and develop drugs based on our SNÅP platform is novel and unproven.
- Potential delays in the commencement, enrollment, and completion of preclinical studies and clinical trials.
- Dependence on third parties in connection with manufacturing, research and preclinical testing.
- Unexpected adverse side effects or inadequate efficacy of our product candidates that may limit their development, regulatory approval, and/or commercialization.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q4 2021
+2.0%
Avg return
Earnings day
+3.0%
Avg return
5 days after
-0.8%
Avg return
30 days after
50%
9 / 18 earnings
Positive
+29.8%
Q3 2021
Best reaction
-11.5%
Q4 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +1.5% | +7.7% | +21.8% | |
| Q3 2025 | +0.3% | +8.4% | +50.6% | |
| Q2 2025 | +0.4% | -4.3% | +17.0% | |
| Q1 2025 | -3.1% | -4.0% | +2.3% | |
| Q4 2024 | -0.8% | -10.5% | +3.9% | |
| Q3 2024 | -5.9% | -6.9% | -8.1% | |
| Q1 2024 | -3.8% | +3.1% | +9.7% | |
| Q4 2023 | +7.0% | +3.0% | -9.7% | |
| Q3 2023 | -6.3% | -8.1% | +2.5% | |
| Q2 2023 | +0.9% | +1.6% | -3.4% | |
| Q1 2023 | -3.3% | +7.0% | +13.1% | |
| Q4 2022 | -3.3% | +0.0% | -9.8% | |
| Q3 2022 | -7.1% | +12.9% | -3.1% | |
| Q2 2022 | +11.1% | +14.7% | -24.0% | |
| Q1 2022 | +0.1% | -5.9% | -17.8% | |
| Q4 2021 | -11.5% | -5.3% | -6.4% | |
| Q2 2021 | +29.8% | +20.3% | -26.6% | |
| Q3 2021 | +29.8% | +20.3% | -26.6% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro